Indication
Circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Loading your page…
Loading your page…
Sleep Initiation and Maintenance Disorders
Marketing Authorisation Holder: RAD Neurim Pharmaceuticals EEC SARL
EMA Authorisation: 29/06/2007
INN: melatonin
AI Drug & Interaction Analysis
Free account required
Ask Osler about Circadin: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.